Hormel Foods Corp vs Mesoblast Limited — how do they compare? Hormel Foods Corp trades at $23.94 (market cap $13.37B), while Mesoblast Limited trades at $16.98 (market cap $2.21B). The key difference: Hormel Foods Corp is far larger — about 6× Mesoblast Limited's market cap, and Hormel Foods Corp pays a 4.81% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| HRL | MESO | |
|---|---|---|
Market Cap | $13.37B | $2.21B |
Sector | Consumer Staples | Technology |
52-Week High | $29.25 | $20.96 |
52-Week Low | $19.74 | $12.88 |
Enterprise Value | $15.37B | $2.21B |
Dividend Yield | 4.81% | — |
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $24.705, down 1.26% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 EPS of $0.40, beating expectations, but net income margin declined to 3.82% in 2025. Recent news includes the appointment of John Ghingo as CEO and the sale of its Brazilian CERATTI business, signaling strategic refocusing.
Outlook is mixed: strong dividend yield and consistent earnings beats support income investors, but margin pressures and bearish technicals pose near-term risks. Analyst consensus is 'Hold' with a $26.33 price target, suggesting limited upside. Macroeconomic headwinds in consumer staples may challenge growth.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →